(IN BRIEF) Fresenius Kabi has licensed rights from Polpharma Biologics to commercialize the vedolizumab biosimilar candidate PB016 globally—except in the Middle East and North Africa—once approved. Vedolizumab treats Crohn’s disease and ulcerative colitis, and PB016 references Takeda’s Entyvio®. The transaction … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Poland, Science, Technology
Tagged #FutureFresenius, (Bio)Pharma portfolio, chronic inflammatory diseases, Crohn's disease, denosumab biosimilar, Dr. Sang-Jin Pak, EC Approval, Entyvio, FDA approval, Fresenius Kabi, global commercialization, Konstantin Matentzoglu, licensing agreement, partnership, PB016, Polpharma Biologics S.A., Ulcerative colitis, Ustekinumab Biosimilar, vedolizumab biosimilar
(IN BRIEF) The European Commission has approved Fresenius Kabi’s denosumab biosimilars, Conexxence® and Bomyntra®, for all uses of the originator product. These include osteoporosis treatment for postmenopausal women and at-risk men, mitigation of treatment-related bone loss, prevention of skeletal complications … Read the full press release
Posted in Business, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged #FutureFresenius, Biopharma platform, Bomyntra, cancer metastasis to bone, Conexxence, denosumab biosimilar, Europe, European Commission approval, Fresenius, Fresenius Kabi, Fresenius Kabi Deutschland GmbH, giant cell tumor of bone, high-quality biosimilars, osteoporosis, postmenopausal women, registered trademarks, skeletal complications, treatment-related bone loss
(IN BRIEF) Fresenius Kabi’s Santiago de Besteiros plant in Portugal has secured BSI Kitemark™ Certification for Minimized Risk of AMR in its Ceftriaxone production, confirming compliance with the AMR Industry Alliance’s Antibiotic Manufacturing Standard. Key measures include stringent controls to … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Portugal, Science, Technology
Tagged AMR, AMR Industry Alliance, antibiotic efficacy, Antibiotic Manufacturing Standard, antimicrobial resistance, BSI Kitemark Certification, Ceftriaxone, Cristina Fernandes, EHS Management, emissions control, environmental protection, Fresenius Kabi, partnership, PORTUGAL, responsible pharmaceutical production, Santiago de Besteiros, sustainability, wastewater management, Zyad Hatquai
(IN BRIEF) South African clinical dietitian Lizl Veldsman has won the 2025 Harry M. Vars Award from ASPEN for her innovative ICU study supported by Fresenius Kabi. The study examined the impact of intravenous protein and in-bed cycling on muscle … Read the full press release
Posted in Awards, Business, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Science, Technology
Tagged Ajar K. Jain, ASPEN, ASPEN 2025, Awards, clinical nutrition, critical care, early-career researcher, Fresenius Kabi, global health research, Harry M. Vars Award, ICU muscle mass, in-bed cycling, intravenous amino acids, JUMPstart Clinical Nutrition Program, leadership, Lizl Veldsman, nutrition mentorship programs, parenteral nutrition, randomized controlled trial, Renée Blaauw, South Africa, Stellenbosch University, sustainability in clinical care, Tygerberg Hospital
(IN BRIEF) Fresenius Kabi is addressing the global threat of antimicrobial resistance (AMR), which causes millions of deaths annually, through sustainable manufacturing, improved antibiotic access, and promoting responsible use. During AMR Awareness Week, the company highlighted its commitment to reducing … Read the full press release
(IN BRIEF) Fresenius Kabi, in collaboration with Formycon, has received approval from the European Commission (EC) for FYB202, a biosimilar of ustekinumab (marketed as Stelara® by Johnson & Johnson). This biosimilar is approved for the treatment of serious inflammatory diseases. … Read the full press release
Posted in Business, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Formycon, Fresenius Kabi, FYB202, partnership, safety, Stelara®, sustainability, Ustekinumab Biosimilar
(IN BRIEF) Fresenius Kabi, in partnership with Formycon AG, has received European Commission approval for Otulfi®, a biosimilar of ustekinumab. This new product, authorized for both subcutaneous and intravenous formulations, will treat inflammatory conditions such as Crohn’s disease, plaque psoriasis, … Read the full press release
Posted in Business, Environment, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Dr. Sang-Jin Pak, Formycon AG, Fresenius Kabi, inflammatory diseases, Otulfi®, partnership, safety, sustainability, Ustekinumab Biosimilar
(IN BRIEF) Fresenius Management SE has extended Sara Hennicken’s term as Chief Financial Officer (CFO) until 2027, two years earlier than planned, to ensure continuity in advancing the #FutureFresenius strategy. Hennicken, who joined Fresenius in 2019, has been instrumental in … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Management, Pharma & Biotech, Technology
Tagged #FutureFresenius, CFO, Chief Financial Officer, Deutsche Bank, finance, Fresenius, Fresenius Helios, Fresenius Kabi, Fresenius Management SE, Fresenius Medical Care, Sara Hennicken, Supervisory Board, transparency, Wolfgang Kirsch
(IN BRIEF) Fresenius Kabi announces FDA approval of Tyenne® (tocilizumab-aazg), the first tocilizumab biosimilar offering both IV and subcutaneous formulations. This marks a significant milestone in the company’s growth strategy (#FutureFresenius) and expands treatment options for inflammatory, autoimmune diseases, and … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech
Tagged #FutureFresenius, Actemra®, autoimmune diseases, Biosimilar, Cancer, cancer treatment, FDA, Food and Drug Administration, Fresenius Kabi, Genentech, Idacio®, inflammatory, inflammatory diseases, IV, IV formulation, Stimufend®, Subcutaneous formulation, subcutaneous tocilizumab biosimilar, tocilizumab, tocilizumab biosimilar, tocilizumab-aazg, Tyenne®
(IN BRIEF) Fresenius had a strong finish in 2023, with a robust fourth quarter performance. They project accelerated earnings growth in 2024 due to the momentum from their #FutureFresenius initiatives. Achieving their raised outlook for FY/23, the company saw continued … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?